Stock Analyst Update on Sarepta Therapeutics Inc (NASDAQ:SRPT)

Sarepta Therapeutics Inc (NASDAQ:SRPT) (TREND ANALYSIS) NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray. Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin’s (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin. :theflyonthewall.com

Stock Performance: Click here for a free comprehensive Trend Analysis Report

Sarepta Therapeutics Inc (NASDAQ:SRPT) stock is currently trading 13% below its 52-week-high, 154.63% above its 52-week-low. The 1-year stock price history is in the range of $11.33 – $33.16. Sarepta Therapeutics Inc (SRPT) has a price to book ratio of 6.44 versus Healthcare sector average of 123.65. SRPT stock price has outperformed the Nasdaq by 110%. The Therapeutics company is currently valued at $1.2 billion and its share price closed the last trading session at $28.85. The stock has a 50-day moving average of $24.97 and a 200-day moving average of $16.42.

Sarepta Therapeutics Inc (SRPT) current short interest stands at 15.07 million shares. It has increased by 2% from the same period of last month. Around 64% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.57 million shares, the number of days required to cover the short positions stand at 9.7 days.

The company is expected to announce next quarter earnings on August 06, at consensus estimate of $-1.21. Sarepta Therapeutics Inc (SRPT) reported last quarter earnings on May 07. The Therapeutics company announced earnings per share of $-1.49 against a consensus Street estimate of $-1, missing estimate by $0.49. This corresponds to a decrease of $0.25 compared to the same quarter of the previous fiscal year.

Is this a Buying Opportunity? Click here for a free Trend Analysis Report

There are currently fifteen analysts that cover Sarepta Therapeutics Inc stock. Of those fifteen, eight have a Buy rating, seven have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $31.23.

A recent analyst activity consisted of Bank of America downgrading their Buy rating to Neutral on May 21. Bank of America increased their price target on SRPT from $20 to $28. This corresponds to a 2.95% downside from the last closing price. On the date of report, the stock closed at $24.26.

Canaccord Genuity upgraded their Hold rating to Buy on May 20, and increased their price target on SRPT stock from $16 to $30. This corresponds to a 3.99% upside from the last closing price. On the date of report, the stock closed at $26.24.

Another research firm was SunTrust Robinson Humphrey who upgraded their Neutral rating to Buy on May 20. SunTrust Robinson Humphrey increased their price target on Sarepta Therapeutics Inc from $14 to $33. This translates to a 14.38% upside from the last closing price. On the date of report, the stock closed at $26.24.

Company profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. The Company offers its products to the medical industry in countries around the world.

Stock Analyst Update on Sarepta Therapeutics Inc (NASDAQ:SRPT) was last modified: June 29th, 2015 by Kelly Rhodes